SkelRegen Welcomes Director of Scientific Affairs to Management Team
Published: Apr 23, 2013
WEST CHESTER, Pa., April 23, 2013 /PRNewswire/ -- SkelRegen, LLC, the leader in small molecule musculoskeletal tissue regeneration and the first to identify multiple small molecules that are osteoinductive and target different aspects of the musculoskeletal tissue formation pathway, today announced the hire of John M. Wozney, Ph.D. as Director of Scientific Affairs and Co-Owner. In his role at SkelRegen, Wozney will set experimental design and direction; lead collaboration with development partners; build alternative R&D pathways; and optimize project quality, cost and time variables.
Wozney is an internationally recognized expert in the key-signaling molecules involved in the growth and maintenance of bone and soft tissues called bone morphogenetic proteins (BMPs), and musculoskeletal biology. He joins the SkelRegen team from the Genetics Institute (acquired by Wyeth and subsequently Pfizer), where he conducted research leading to the identification of BMP. He then played a key role in the commercialization of a genetically engineered protein (rhBMP-2) and the development of a local delivery system as an innovative bone-inductive therapeutic, which has found widespread use in orthopaedics.
In his role at SkelRegen, Wozney brings more than 25 years' experience in the pharmaceutical industry and scientific leadership to help grow the company as it leads the way in small molecule musculoskeletal tissue regeneration. "John brings a unique set of skills, experience and perspective to our business and we are delighted to have him join the team," said Stephen R. La Neve, SkelRegen's Co-Founder and CEO. "His accomplishments, reputation and understanding of our business will help SkelRegen bring our game-changing technologies to the bedside, and strengthen our business of small molecule musculoskeletal tissue regeneration."
"John's knowledge and proficiency in orthobiologics builds on the strength of SkelRegen's value proposition," said SkelRegen Co-Founder and Chief Medical, Science and Technology Officer, Scott D. Boden, M.D. Boden is Chief Medical Officer and Director of the Emory University Orthopaedic & Spine Hospital and Professor of Orthopaedics, Emory University School of Medicine. "As Director of Scientific Affairs, John will ensure that SkelRegen's platform of small molecule technologies for transforming musculoskeletal care continues to provide cutting-edge solutions for those in orthopaedic surgery, trauma and plastic surgery."
"I am thrilled to be part of the SkelRegen team," said John Wozney. "As someone who has been in the industry for almost three decades, I am sure the work that SkelRegen is doing right now is leading the way in orthopaedic small molecule technology and I'm proud to be part of this revolutionary approach to musculoskeletal tissue regeneration."
Wozney is the author of more than 150 peer-reviewed publications and is an inventor on more than 50 issued U.S. patents. He received both his A.B. and Ph.D. degrees in biochemistry from Harvard University and was a post-doctoral fellow at Massachusetts Institute of Technology.
SkelRegen, LLC was formed in the state of Delaware in September 2012. The company maintains its headquarters in West Chester, PA. For more information on the company, its products, or investment opportunities, please visit the company's website at SkelRegen.com or call the company's media contact directly.
Contact: Shannon Webber
(412) 749-9299 x103
This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.